UES for excellence	Simulation Scenario		NHS Frimley Health NHS Foundation Trust
Title	Tricyclic Antidepressant (TCA) Overdose	Version	2.7
Target Audience	FY doctors & student nurses	Run time	10 -15 mins
Authors	James Foxlee, Simon Clark, Monica Minardi, Claire Linkins, Claire Jackson, Udesh Naidoo, Paul Wilder, Mark Loughrey (Concept inspired by RCEM)	Last review	25/7/18
Faculty comments	Extra faculty can play the role of patient relative	Necessity	DESIRABLE

Brief Summary

A young patient has taken a tricyclic antidepressant (TCA) overdose a few hours prior to admission but doesn't immediately admit to it. The patient is initially slightly drowsy and disorientated and then becomes unresponsive with decreased respiratory rate and hypotension. The patient will need immediate supportive management followed by ITU care.

Educational Rationale

FY doctors often face fast moving situations in which they must be able to assess, communicate and know when to change from assessment to resuscitation as the patient deteriorates.

Learning Objectives: Nurse

- A-E assessment of an acutely deteriorating patient
- Appropriate escalation of an unstable patient
- SBAR handover

Learning Objectives: Doctor

- A-E assessment of an acutely deteriorating patient
- Awareness of differential diagnosis for altered consciousness
- Medical management of reduced consciousness and tricyclic antidepressant overdose
- Communication with patient and SBAR handover with colleagues



No	CURRICULUM MAPPING	This scenario
1	Acts professionally	\checkmark
2	Delivers patient-centred care and maintains trust	\checkmark
3	Behaves in accordance with ethical and legal requirements	\checkmark
4	Keeps practice up to date through learning and teaching	\checkmark
5	Demonstrates engagement in career planning	
6	Communicates clearly in a variety of settings	\checkmark
7	Works effectively as a team member	\checkmark
8	Demonstrates leadership skills	\checkmark
9	Recognises, assesses and initiates management of the acutely ill patient	\checkmark
10	Recognises, assesses and manages patients with long term conditions	
11	Obtains history, performs clinical examination, formulates differential diagnosis and management plan	\checkmark
12	Request relevant investigations and acts upon results	\checkmark
13	Prescribes safely	\checkmark
14	Performs procedures safely	\checkmark
15	Is trained and manages cardiac and respiratory arrest	(√)
16	Demonstrates understanding of the principles of health promotion and illness prevention	\checkmark
17	Manages palliative and end of life care	
18	Recognises and works within limits of personal competence	\checkmark
19	Makes patient safety a priority in clinical practice	\checkmark
20	Contributes to quality improvement	

Candidate Briefing: Nurse

Setting A&E Majors

You are in triage in A&E Majors. A young female patient has just arrived after calling herself an ambulance.

The paramedics found her withdrawn, upset and tearful; she initially refused to talk to them.

She was initially tachycardic with the crew but observations were otherwise unremarkable.

Whilst the paramedics were with her she started becoming confused and was brought in.

Please do basic observations and enter these on the cas card, then escalate as appropriate.

Candidate Briefing: Doctor

Setting A&E Majors

You are on call for medicine. Please wait as directed, until you receive a call from A&E Majors and then act as you would do in real life.

	Technical set-	up	
Setting	A&E Majors		
Simulator	High fidelity manikin		
Gender	Female	Age	22

	Initial	monitor	paramet	ers
RR	O2 sats	Pulse (HR)	BP	ECG rhythm
11	97% on air	130	98/50	Broad complex tachycardia
Cap Refill Time	Blood glucose	Temp.		
3s	4.2	37.0		

	Initial	ра	tient se	et-up		
	Obstruction			Airway adj	unct	
Airway	No			No		
Duesthing	Chest sounds			O2 supply		
Breathing	Clear			Air		
Circulation	Heart sounds	Car	nnula	BP cuff		Peripheries
Circulation	Normal	No		No		Warm, dry
		1				
Dischilling	Eyelids		Pupils		Α١	/PU/GCS
Disability	Open		Dilated		А	/ 15
Evposuro	Posture		Moulage		В	owel sounds
Exposure	Supine		None		S	luggish

Specific equipment / prop requirements

- Monitoring: ECG, non-invasive BP (cuff), pulse oximeter all unattached
- Crash trolley available outside
- Wig
- Patient name band
- A&E admission proforma (not completed, not seen by A&E)
- Blank CAS form and drug chart
- ABG (on request)
- ECG (on request)
- Chest x-ray (on request)
- Printout of Toxbase guideline for TCA overdose (on request)
- TCA Overdose guidance handouts for debrief

DRUGS

- iv fluids (gelofusine, NaCl, Hartmann's, Plasmalyte)
- Sodium Bicarbonate (8.4%) 50ml x3 Minijets

Facilitator Briefing

SCENARIO FLOW

After evaluation by candidate doctor if patient has not been questioned sufficiently to admit to OD before decreasing consciousness:

•a call comes through stating that the distressed mother has rung the hospital to say that she is on route but her amitriptyline tablets are missing and she believes her daughter has taken nearly her whole packet OR

mother enters room (see Relative Briefing)

TELEPHONE ADVICE - MED REG / ITU REG

The ITU / Medical Registrar should press the candidate hard about what assessment has been performed, what they think the problem is and what management has been commenced

TELEPHONE ADVICE - TOXICOLOGY CENTRE / PHARMACIST

If candidates contact a toxicology centre and provide the correct diagnosis then inform them that the patient may receive decontamination with activated charcoal if < 2 hours, intravenous fluid, sodium bicarbonate, vasopressors, may require intubation

Telephone advice

- You will be sitting in the control room for the duration_
- Answer all calls as "switchboard" in the first instance to allow for realistic delay.

How to run with candidates from only one discipline

An additional member of faculty can play the role of the nurse in this scenario if needed.

Sim Nurse briefing:

You are a nurse working in A&E Majors. A young patient has just arrived via ambulance. The paramedics found her withdrawn, upset and tearful; she initially refused to talk to them.

She was initially tachycardic with the crew but observations were otherwise unremarkable. Whilst the paramedics were with her she started becoming confused and was brought in.

The patient has been complaining of blurred vision. She is becoming disoriented and you are increasingly concerned about her. You have called for urgent review.

Patient's relative briefing

You are the patient's mother

- Enter scenario at an appropriate time
- Penny is a 22 year old university student who lives at home and has no known allergies nor takes any regular medication
- Penny broke up with her long term boyfriend earlier today
- Penny came home from university upset and tearful, wouldn't talk about it. She then went out
- You received a call later from the hospital
- You are willing to move away from the bedside but not out of the room
- If you are not kept informed of what is happening then become distressed
- Your husband died a few months ago in a car crash
- You have been suffering depression and earlier this week were prescribed antidepressants (amitriptyline)

The objective is for the candidate to communicate with you and quickly deduce that the patient has taken a TCA overdose

	Patient Briefing
Setting	A&E Majors
Name	Penny Tapp
Age	22
Gender	Female

What has happened to you?

You took an overdose of your mother's pills 2-3 hours ago and later called an ambulance, but were too embarrassed to admit what you had done to the paramedics.

How you should role-play

- Complain of blurred vision and keep asking for water (dry mouth)
- Act disorientated this deteriorates fairly rapidly over course of scenario
- Act **upset** and talk about breaking up with your boyfriend earlier today
- Upset about father dying and mother not understanding her

• FY1 candidates: The objective is (before suffering decreased consciousness) for the candidate to question you and quickly learn that you're upset > you've taken something > it's your mother's pills > they were for depression > it's amitriptyline. If they fail badly in this (e.g. you lose consciousness first) then there will be a phone call from the mother to explain

 $\bullet FY2$ candidates: If there is a facilitator playing the mother then the communication of the OD will be shared between you with the mother

•Nurse candidates: If there is one then the doctor won't be called until they request one follow above instructions but don't get as far as confirming to the nurse that you've taken an overdose

Your background

PAST MEDICAL HISTORY


- Nil of note
- No regular medication
- No known drug allergies

SOCIAL HISTORY

- University Student
- •You split up from your long-term boyfriend this morning
- •Your father died in a car crash a few months ago

•You are not very close to your mother and "she never listens to you". She has depression and difficulty sleeping and was prescribed the amitriptyline earlier this week

Scenario flowchart




References

- Guideline for the management of tricyclic antidepressant overdose. The College of Emergency Medicine. <u>https://www.rcem.ac.uk/docs/College%20Guidelines/5z32.%20Tricyclic%20Antide</u> pressant%20Overdose%20-%20(Flowchart)%20(Dec%202009).pdf
- NICE Clinical Knowledge Summaries. Poisoning or overdose; Scenario management. June 2017. Found at: <u>https://cks.nice.org.uk/poisoning-or-overdose#!scenario</u>


Clinical props

RADIOMETER ABL800 FLEX

Ide	ntificati	ons						-		
	atient ID		789987							
Pa Se	atient Las atient Firs ex ate of bin	at Name	TAPP Penny Female							
	D,(I)			96						
Т			37.0	С						
	ample typ perator	e	Arterial TEMP	FPH 1						
		s Values					-	-		
1	pH	s values	7,220			r	7.350	47	450	1
•	pCO		5.30			i	4.70			1
	p00,		12.0			ſ	11.1			1
	Hctc		41.90			•	0.000		00000	
0	and a start of the second	Values	12150	1.0						
	ctHb		12.4	g/L						
	FO,H	lb	96.0			1	94.0	-	98.0	1
	sO,		96.0			-				-
↑	FCO	НЬ	2.5			[0.5		1.5	1
-	FHH	2	0.1	%		i	0.0	-	5.0	1
	FMe	Hb	0.2	%		i	0.0	-	1.5	1
Ca	alculate	d Values								
	cBas	e(Ecf)c	-8.0	mmo	I/L					
	cHC	O,-(P)c	16.0	mmo	VL.					
E	ectrolyt	e Values								
	cNat		139	mmo	I/L	1	136	-	146	1
	cK*		4.0	mmo	WL.	1	3.4	-	4.5	1
	¢Cl⁻		106	mmo	I/L	[98	-	106]
	cCa	+	1.21	mmo	WL.	[2.2	-	2.45]
		n Gap _c	21.0	mmo	I/L					
M	etabolit	e Values								
	cGlu		4.2	mmo	J/L	[3.9	-	:5.8	1
Ť	cLac	2	4.0			1			1.6	1
	cCre	a	88	μmo	٧L	1	44	-	97	1
Not	tes									
1		Value(s) a	bove refe	rence rar	nge					
+		Value(s) t			ge					
c		Calculated	value(s)							








Surname: Tap	0								First	nan	ne:	Pe	nn	14										Fri	m	ey	Health
lospital number:	2345					D.	0.B:				17			te of a	dmi	ssion	: 1	60	a	•							ation Trus
iospital traine of g	DATE		-		-	-	1	-	-	1	_	-		1000				- 1		-	-	=					DATE
	TIME	-		-		-	-	-																-			TIME
	≥25								Children of			-	-	3					14.			190		120			≥25
A+B	21-24										1.1			2													21-24
espirations	18–20																	_		_							18-20
reaths/min	15–17				_	_		_		_									_	_	-	_		_		_	15-17
	12-14	81				-	_			-		_			-		-			-	-	_				-	12–14 9–11
	9–11 ≤8								CONC.	1010				1								1004	0.000	a first			5=11
		0.4								1 2001											-	-		_			≥96
A+B	≥96 94–95	97			-	-								1				-			-						94-95
SpO2 Scale 1	92-93	100		199								100		2													92-93
Dxygen saturation (%)	≤91				5160					4.70				3									i ori				≲91
5p02 Scale 2 ^t	≥97 on O ²												/	3												/	≥97 on 0 ²
)xygen saturation (%)	95-96 on O,		1									/		2										/			95-96 on 02
Jse Scale 2 if target ange is 88–92%,	93-94 on O2									1				1								/	/				93-94 on 0,
eg in hypercapnic	≥93 on air								/				-							\rightarrow	/				\vdash		≥93 on air
espiratory failure	88-92								-	_								-	1			-	_	_			88-92 86-87
ONLY use Scale 2	86-87 84-85					1								1			/										84-85
nder the direction of gualified clinician	<u>84–85</u> ≤83%			/		(07522)	0.00	2 100		100	11503		1000	3	1	1		CARDINE I	101	10.0	100	1997	8039		1949		≤83%
	A=Air	A.											-	101212							1						A=Air
Air or oxygen?	O2 L/min	A												2													O2 L/min
	Device													10.0													Device
														122.010													
C	≥220			1			24			120			1	00	124								200				≥220
	201-219													10.2		_											201-219
Blood pressure	181-200			_			_				-	-	-		\vdash	-		_		_		_					181-200 161-180
core uses	161-180		_	-			_	_	-	-	-	-	\vdash	100	⊢	-	_			-	_						141-160
systolic BP only	141-160					-	-		-	-		-	+		\vdash					-			-				121-140
	121-140		-	-				-	-			-		2.2		-					-						111-120
	101-110	98												1													101-110
	91-100	~					177	3.1	de					2	-												91-100
	81-90	1						24				-			1940	1					12.3					2	81-90
	71-80	1				1		1										_			1.00	-			-	12	71-80 61-70
	61-70	1	110								-	-		3	1						12.00						51-60
	<u>51–60</u> ≤50	4												1.6													≤50
		30												3							Service P	-					≥131
C	≥131 121-130	130		-					1111																		121-130
Pulse	111-120	130												2													111-120
Beats/min	101-110																										101-110
	91-100													'													91-100
	81-90											-	1		_	-									\vdash	-	81-90
	71-80			-	-				-	_	-	-	+		-	-		-	-		_	-	-		-	-	71-80 61-70
	61-70	-	-	-	-		-	-	-	-	-	-	+		-	-	-	-			-	-	-		\vdash		51-60
	51-60 41-50													1	-												41-50
	31-40		1091	100				1910										103				Ref.	1.1	1200			31-40
	≤30													3					1960								≤30
-	Alert	A	-	T					1	1	T	1	1														Alert
D	Confusion		1								100		1 million			-		100	100							146	Confusion
Consciousness	v						22			100				3		100									-	-	V
Score for NEW onset of confusion (no score if chronic)	Р																			1.50				-	-	-	P
score if chronic)	U																		-					-	-	-	U
E	≥39.1°													2													≥39.1°
L	38.1-39.0°													1										-	-	-	38.1-39.0° 37.1-38.0°
Temperature °C	37.1-38.0°		2	-	-	-		-	-	-	-	-	+		-	-	-	-	-	-	-	-	-	+	+	-	37.1-38.0° 36.1-37.0°
	36.1-37.0°		F											1													35.1-36.0°
	35.1-36.0° ≤35.0°				U.C.M			1000			100			3				1.00									≤35.0°
NEWS TOTAL	555.0	4	-	-	-	1	1				-	T	-			T	1	T	T				T		T		TOTAL
NEWS TOTAL		-	-	-	-	-	-	-	-	-	1	+	1	1	1	T	T	-	1	1		-	T	1	1	T	Monitoring
Moni	Pain score	_	-	+	+	+	-	-	-	-	+	+	+	1	F	1	1	+	1	-		-	1	\vdash	1	1	Pain score
	Pain score Initials	_	+	-	-	+	-	+	-	-	+	+	+	1		+	1	+	1	-		1	1	1	1	-	Initials

				NHS Fo	undatio	spital NH
Hospital Number: 7	89987					
NHS Number:					riintin hiint	, , , , , , , , , , , , , , , , , , ,
Title: 0153 DoB: Sumarne. NA First name: PA Address: PA	Sex: F Age: 201 W	irs ·	Address:	notter one as	. /	Y. (3)
Postcode Tel (H): (Tel (M):			NOK: Address:			
Employer / Equc. E Religion: 1 Language:	st.		Relationship Tel (H): Tel (M):):		
Source of Referral: Date of Arrival: Time of Arrival: Mode of arrival: No of Attendances		2	GP: Address: Tel No:			
Previous Attendand	e Number: EL	0-12-051816-1	Fax No:			
To be seen in: / M	layors	4 21 21 1989		and the t		1
Speciality Expected Specialty:	1:	Time referred to Time seen:	specialty:	Duty/Or		gency Department ultant:
Presenting Compla	int:	6 22		1	-** - *	1
Triage Nurse: C.	JACKSON			Time of Triage		
Presenting Complaint: a	م نامن	u		Triage (ESI)	- 3	
History of Presenting Co	mplaint: P+ o	+ peusit	conved	Pain Score	1	
On Assessment: Previous Medical History Social History:	Kelic	taut to a	Connuc-	Allergies	nder Velage	221
				Tetanus Status		
				Triage Treatment		
				Triage Notes	5	
Terretor	36.8°C	Blood Press	re 985	O Nurse C	oncern	
Temperature	130	SP O ² (Air)	971.	GCS		E V M ⊒∜15
Pulse	1.50					
	11	Pupils (Left)		Pupils (F	Right)	
Pulse		Pupils (Left) Blood sugar		Pupils (F Weight	Right)	

Name	Signature	Initials	Position	Speciality	Date	Time
	ave you considered lease refer to the Y / N					
	121728					
Presenting Comple	aint:					
HISTORY: (Please	continue on cont	inuation sheet	s if necessary)			
histort. (Fiease	continue on cont	indation shoel	an noossary)		Age >65	
					3 Coronary Disease (C/ Risk Factor Family histo raised chole diabetes me hypertensio active smok	ry, sterol, illitus,
					Known CAE stenosis >5	0%
					Aspirin use 7 days	in past
					Recent (<24 severe angi	hours)
					Raised card markers (Cl	iac
					ST deviation	
					TIMI	Risk re
					A	
					Age >60 BP >140/90	
					Clinical feat Unitat weak Speech onl	(2 pts)
					Duration: >60 mins (10-59 mins <10 mins (0	(1 pt)
					Diabetic	
					Score (n	nax 7)
Women of Childbea	aring age? LMP		Preg	nant? Y / N		

	174			
	DAF	☐Hx Dementia	Hypertension	IHD/Angina
Diabetes		Epilepsy	Asthma	Pacemaker
(Please tick relevan	t conditions if pres	sent)		
Drugs				
				-
Allergies				
Allergies Dru	9		Reaction	Date
Allergies Dru	g		Reaction	Date
	9		Reaction	Date
	g		Reaction	Date

Family History		
Social History		
Alcohol:units/week	Smoking:	
Occupation:	Retired: Yes /	10
Lives in: House / Flat / Bungalow / WO	F / Residential Home / Nursin	g Home/ Barracks
Surrey / Hampshire / Berkshire/ Other		-
		Chaires Mars (No.
Usually able to go out: Yes / No	Lives alone: Yes / No	Stairs: Yes / No
Mobility: Independent Service		
Stick Frame	Bathing services District Nurse	Spouse Other family
Wheelchair	District Nurse	Other family Friend/ Neighbour
	Day Hospital	
Driver Ver (No	,,	-
Drives: Yes / No		
Has memory deficit been present for 6		□ No
Drives: Yes / No Has memory deficit been present for 6 AMT (N/A)	months or more? □Yes	
Has memory deficit been present for 6 AMT (N/A) Age Recognition of tw	months or more?	rest hour) Date of Birth
Has memory deficit been present for 6 AMT (N/A) Age CRecognition of tw Address for recall WW	i months or more? □Yes vo persons □Time (to near /2 □ Year	
Has memory deficit been present for 6 AMT (N/A) Age Recognition of tw	i months or more? □Yes vo persons □Time (to near /2 □ Year	rest hour) Date of Birth



Neurolo	Ņ	ļ	.g Hosp No.	: 789	987	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	200
GCS:	E	 V		М		 /15	
Pupils:		 					

Cranial Nerves: (Not Assessed - tick here:)

Abnormalities:

Peripheral Nerves: (Not Assessed - tick here:)


.

		Pov	wer	1	Refle	exes	To	ne
		Right	Left		Right	Left	Right	Left
Shoulders	abd (c5,6)							
	add (c5,6,7)							1
Elbow	flex (c5,6)			Biceps (c5,6)				1
	ext (c7,8)			Triceps (c7,8)				
Wrists	flex (c6,7,8)			Supinator (c6)				
	ext (c7,8)							
Hips	flex (I1,2,3)							
	ext (15,s1,2)			112.20			· ·	
	abd (i4,5,s1)				S			
	add (12,3,4)					1.0		
Knees	flex (14,5,s1,2)			Knee (I2-4)				
	ext (12,3,4)							
Ankles	flex (14,5,s1,2)			Ankle (s1,2)				1
-	ext (s1,2)			Plantar (I5-s2)				

Cerebellar Signs:

Nystagmus	Gait
Finger/Nose	Dysdiadokoinesis
Heel/shin	Dysarthria
Romberg's test	


6



Investigations: CXR AXR CT Head Other Results:	Radiology:	s: DCXR [
Investigations: Radiology: CXR AXR CT Head Other	Radiology:	s: DCXR [
Investigations: Radiology: CXR AXR CT Head Other	Radiology:	s: DCXR [1.00			
Radiology: CXR AXR CT Head Other Results: Bloods: FBC Coag / INR ESR U&Es LFTs Bone CRP Other	Radiology:	OCXR [
Results: Bloods: FBC Coag / INR ESR U&Es Bone CRP Other			1.000			
Bloods:FBCCoag / INRESR U&EsLFTsBoneCRP Other Results: Image: MCV	Results:	~	JAXR UC	rHead □ C	Other	
Bloods: FBC Coag / INR ESR						
Bloods: FBC Coag / INR ESR						
Bloods: FBC Coag / INR ESR						
Bloods: FBC Coag / INR ESR						
Bloods: FBC Coag / INR ESR						
Bloods: FBC Coag / INR ESR						
Bloods: FBC Coag / INR ESR						
U&Es LFTs Bone CRP Other Other Results: Hb MCV Na Bil AST Chol VCC B12 K Alk P GGT HDL Neut Folate Ur ALT Amylase TG Pit PT Creat Alb CK LDL ESR APTT Glucose P04 Trop (1) TSH U INR CRP Cor Ca Trop (2) FT4 Others: BECG Urine BHCG ABG Other						
U&Es LFTs Bone CRP Other Other Results: Hb MCV Na Bil AST Chol VCC B12 K Alk P GGT HDL Neut Folate Ur ALT Amylase TG Pit PT Creat Alb CK LDL ESR APTT Glucose P04 Trop (1) TSH U INR CRP Cor Ca Trop (2) FT4 Others: BECG Urine BHCG ABG Other						
U&Es LFTs Bone CRP Other Other Bill AST Chol WCC B12 K Alk P GGT HDL Neut Folate Ur ALT Amylase TG Pk PT Creat Alb CK LDL ESR APTT Glucose P04 Trop (1) TSH Uhers: INR CRP Cor Ca Trop (2) FT4	Bloods: DI	BC Co	ag / INR 🛛	ESR		
Other MCV Na Bill AST Chol WCC B12 K Alk P GGT HDL Neut Folate Ur ALT Amylase TG Pit PT Creat Alb CK LDL ESR APTT Glucose P04 Trop (1) TSH Uhers: EECG Urine βHCG ABG Other Results: C BHCG ABG Other					RP .	
Hb MCV Na Bill AST Chol WCC B12 K Alk P GGT HDL Integration Neut Folate Ur ALT Amylase TG Integration Pit PT Creat Alb CK LDL Integration ESR APTT Glucose P04 Trop (1) TSH Integration						
Hb MCV Na Bill AST Chol WCC B12 K Alk P GGT HDL Neut Folate Ur ALT Amylase TG Pit PT Creat Alb CK LDL ESR APTT Glucose PO4 Trop (1) TSH INR CRP Cor Ca Trop (2) FT4 Others: BHCG ABG Other Other Results: BHCG ABG Other						
WCC B12 K Alk P GGT HDL Neut Folate Ur ALT Amylase TG IDL Pt PT Creat Alb CK LDL IDL ESR APTT Glucose P04 Trop (1) TSH IDL ESR APTT Glucose P04 Trop (2) FT4 IDL	resound,					
Neut Folate Ur ALT Amylase TG Pit PT Creat Alb CK LDL ESR APTT Glucose P04 Trop (1) TSH INR CRP Cor Ca Trop (2) FT4			Na			and the second s
Pit PT Creat Alb CK LDL ESR APTT Glucose PO4 Trop (1) TSH INR CRP Cor Ca Trop (2) FT4	Hb	MCV	140	Bill	AST	Chol
ESR APTT Glucose PO4 Trop (1) TSH INR CRP Cor Ča Trop (2) FT4 Others: ECG DUrine βHCG ABG Other Other	12.00					
INR CRP Cor Ca Trop (2) FT4 Others: □ECG □Urine □ βHCG □ ABG □ Other	wcc	B12	к	Alk P	GGT	HDL
Others: □ECG □Urine □ βHCG □ ABG □ Other Results:	WCC Neut	B12 Folate	K Ur	Alk P ALT	GGT Amylase	HDL TG
Others: □ECG □Urine □ βHCG □ ABG □ Other Results:	WCC Neut Pit	B12 Folate PT APTT	K Ur Creat Glucose	Alk P ALT Alb PO4	GGT Amylase CK	HDL TG LDL TSH
□ECG □Urine □ βHCG □ ABG □ Other	WCC Neut Pit	B12 Folate PT APTT	K Ur Creat Glucose	Alk P ALT Alb PO4	GGT Amylase CK Trop (1)	HDL TG LDL TSH
Results:	WCC Neut Pit	B12 Folate PT APTT	K Ur Creat Glucose	Alk P ALT Alb PO4 Cor Ca	GGT Amylase CK Trop (1)	HDL TG LDL TSH
	WCC Neut Pit ESR	B12 Folate PT APTT	K Ur Creat Glucose	Alk P ALT Alb PO4 Cor Ca	GGT Amylase CK Trop (1)	HDL TG LDL TSH
	WCC Neut Pit ESR Others:	B12 Folate PT APTT INR	K Ur Creat Glucose CRP	Alk P ALT Alb PO4 Cor Ca	GGT Amylase CK Trop (1) Trop (2)	HDL TG LDL TSH
	WCC Neut Pit ESR Others:	B12 Folate PT APTT INR	K Ur Creat Glucose CRP	Alk P ALT Alb PO4 Cor Ca	GGT Amylase CK Trop (1) Trop (2)	HDL TG LDL TSH
	WCC Neut Pit ESR Others:	B12 Folate PT APTT INR	K Ur Creat Glucose CRP	Alk P ALT Alb PO4 Cor Ca	GGT Amylase CK Trop (1) Trop (2)	HDL TG LDL TSH
	WCC Neut Pit ESR Others:	B12 Folate PT APTT INR	K Ur Creat Glucose CRP	Alk P ALT Alb PO4 Cor Ca	GGT Amylase CK Trop (1) Trop (2)	HDL TG LDL TSH
	WCC Neut Pit ESR Others:	B12 Folate PT APTT INR	K Ur Creat Glucose CRP	Alk P ALT Alb PO4 Cor Ca	GGT Amylase CK Trop (1) Trop (2)	HDL TG LDL TSH
	WCC Neut Pit ESR Others:	B12 Folate PT APTT INR	K Ur Creat Glucose CRP	Alk P ALT Alb PO4 Cor Ca	GGT Amylase CK Trop (1) Trop (2)	HDL TG LDL TSH
	WCC Neut Pit ESR Others:	B12 Folate PT APTT INR	K Ur Creat Glucose CRP	Alk P ALT Alb PO4 Cor Ca	GGT Amylase CK Trop (1) Trop (2)	HDL TG LDL TSH
	WCC Neut Pit ESR Others:	B12 Folate PT APTT INR	K Ur Creat Glucose CRP	Alk P ALT Alb PO4 Cor Ca	GGT Amylase CK Trop (1) Trop (2)	HDL TG LDL TSH
	WCC Neut Pit ESR Others:	B12 Folate PT APTT INR	K Ur Creat Glucose CRP	Alk P ALT Alb PO4 Cor Ca	GGT Amylase CK Trop (1) Trop (2)	HDL TG LDL TSH

	t Plan	:				
				Refe	er? Specia	Y / N lity
		~				(consider VTE prophylaxis)
VTE Risk?	Have	se assess on se e you started VT t - reasons:	parate risk assessment sh E prophylaxis?	neet Y	N	
MRSA Statu	is:		C. Diff status:			
Met Calls	Y	N	For CPR? Orange sticker?	Y Y	N N	
				0		
						-
						-
						-

		pital								
First Nam	ie(s):	ENNY	(Ward		Date char	rt	Chart	numbe
Surname			0				started			
Hospital	Number:	78	3998	7						of
	iber:				Consultan	t	Doctor bl number	eep	Date admi:	
Date weighed	Weight (kg)	Date	Weight (kg)	Height (M)	Surface are (M ²)	a Ide W	eal Body eight (IBW)	Body I Index		Diet
All			16							
Drug/subs	write 'none ki tance	nown [•] and s	ign if none	known). Th	Details of re	COLUMN TWO IS NOT	and the second se	lefore m	edicati	on is gi
Section and							and the second			100
						_				
				-						
				_						
This natie	ent also has t	he followin	n additiona	L charts (co	mplete and	tick rel	evant hoy ((sc))		
	ent also has t	he following	g additiona Chemothera		mplete and	tick re	evant box (MRSA Suppre			
		he following			mplete and	tick re		ssion	n	
IV heparin ir PCA	nfusion chart		Chemothera Epidural	ipy chart		lick re	MRSA Suppre	ssion	n	
IV heparin ir PCA	r: Prescriptio Unclear pro	ns must be r	Chemothera Epidural rewritten n vill be chall	ot amended			MRSA Suppre	ssion	n	
IV heparin ir PCA Reminder	r: Prescriptio Unclear pro	ns must be r escriptions v opioids if ek	Chemothera Epidural rewritten ne vill be chall derly, frail a	ot amender enged ind/or rena	d I impairmen	t	MRSA Suppre Medicines rec	ssion onciliation Si B	n ign and leep lo.	
IV heparin ir PCA Reminder	r: Prescriptio Unclear pro Care with o	ns must be r escriptions v opioids if ek	Chemothera Epidural rewritten ne vill be chall derly, frail a	ot amender enged ind/or rena	d I impairmen	t	MRSA Suppre Medicines rec	ssion onciliation Si B	ign and leep	sign an
IV heparin ir PCA Reminder	r: Prescriptio Unclear pro Care with o	ns must be r escriptions v opioids if ek	Chemothera Epidural rewritten ne vill be chall derly, frail a	ot amender enged ind/or rena	d I impairmen	t	MRSA Suppre Medicines rec	ssion onciliation Si B	ign and leep	Actione sign an date
IV heparin ir PCA Reminder	r: Prescriptio Unclear pro Care with o	ns must be r escriptions v opioids if ek	Chemothera Epidural rewritten ne vill be chall derly, frail a	ot amender enged ind/or rena	d I impairmen	t	MRSA Suppre Medicines rec	ssion onciliation Si B	ign and leep	sign an
IV heparin ir PCA Reminder	r: Prescriptio Unclear pro Care with o	ns must be r escriptions v opioids if ek	Chemothera Epidural rewritten ne vill be chall derly, frail a	ot amender enged ind/or rena	d I impairmen	t	MRSA Suppre Medicines rec	ssion onciliation Si B	ign and leep	sign an
IV heparin ir PCA Reminder	r: Prescriptio Unclear pro Care with o	ns must be r escriptions v opioids if ek	Chemothera Epidural rewritten ne vill be chall derly, frail a	ot amender enged ind/or rena	d I impairmen	t	MRSA Suppre Medicines rec	ssion onciliation Si B	ign and leep	sign an
IV heparin ir PCA Reminder	r: Prescriptio Unclear pro Care with o	ns must be r escriptions v opioids if ek	Chemothera Epidural rewritten ne vill be chall derly, frail a	ot amender enged ind/or rena	d I impairmen	t	MRSA Suppre Medicines rec	ssion onciliation Si B	ign and leep	sign an
IV heparin ir PCA Reminder	r: Prescriptio Unclear pro Care with o	ns must be r escriptions v opioids if ek	Chemothera Epidural rewritten ne vill be chall derly, frail a	ot amender enged ind/or rena	d I impairmen	t	MRSA Suppre Medicines rec	ssion onciliation Si B	ign and leep	sign an
IV heparin ir PCA Reminder	r: Prescriptio Unclear pro Care with o	ns must be r escriptions v opioids if ek	Chemothera Epidural rewritten ne vill be chall derly, frail a	ot amender enged ind/or rena	d I impairmen	t	MRSA Suppre Medicines rec	ssion onciliation Si B	ign and leep	sign an
Date C	r: Prescriptio Unclear pro Care with o	ns must be r escriptions v opioids if ele	Chemothera Epidural rewritten ne vill be chall derly, frail a	ot amender enged ind/or rena	d I impairmen actioned wit	t hin 24	MRSA Suppre Medicines rec	ssion onciliation B N	ign and leep to.	sign an
IV heparin ir PCA Reminder	r: Prescriptio Unclear pro Care with o communicatio	Alcohol	Chemothera Epidural rewritten n vill be chall derly, frail a rs. Message	ot amended enged ind/or rena es must be a	d I impairmen actioned wit	t hin 24	MRSA Suppre Medicines rec hours.	ssion onciliation B N	ign and leep to.	sign an



RISK ASSESSMENT RECORD SHEET FOR VENOUS THROMBOEMBOLISM (VTE)

Please use in conjunction with Trust guidelines overleaf
 Please see separate Trust guidelines for obstetric patients

0

Thrombosis Risk	Patient Related	Procedure Related	Assessment	Assessment at 24 hours	Assessment	Assesses
High	Previous VTE					
	Immobility expected to test >72 hours		-			
	Malignancy					-
	Acute or chronic lung disease					
	Acute or chronic inflammatory disease					-
	Chronic heart failure	-				
	Lower kmb paralysis (excluding acute					
	stroke)		-			
	Acute infectious clasese, e.g. preumonia					
	BMI >30kg/m2					
	Inharitad or acquired thrombophilia					
	Pregnancy or less than 6 weeks post partum					
		Hip or Knee replacement				
		Hip fracture		-		-
		Other major orthopaedic surgery	-			-
		Surgical procedure lasting >30mina				-
Medium	Oestrogen containing onal	with additional VTE risk factor(a)				-
	contraception or HRT	-				
	Selective destrogen receptor modulators					
	Age > 60	1		-		-
	Dehydration		-			
	Varicose vains with philebilis					
		Minor surgical procedure with additional VTE risk factor(a)				
		Surgical procedure lasting >30mins, with no additional VTE risk factors Plaster cast immobiliaation of lower limb				_
Low	None of above	None of above				
Bleeding Risk/ Contraindications	Patient Related	Procedure Related				
a serie della serie della	Haemophilia or other known bleeding					
	disorder Thrombocytopenia (Ptatelets < 100 x 10 ⁵ L)		1			
	Within two weeks of acute stroke (heemonhagic or ischeemic)		-			
	Severe hypertension (BP > 200 systellic or 120 diestolic)					
	Severe liver disease					
	Oesophageal Varices					
	Active Peptic Liber disease					
	Active bleeding or potential bleeding					
	lesions Major bleeding rak, axisting anticoagulant therapy					
	Severe renal disease					_
		Neurosurgery, spinal surgery or eye surgery				
		Other procedure with high taleading risk Lumber puncture/spinallapidural in		_		
fileb and		previous 4 hours or anticipated in next 12 hours				
Risk assessment pe	normed by	and the second				
Signature	-		and the second			
Copy of Patient Infor	rmation Leaflet given to patient		Yes No			

NCE OI	NLY DRUG	S AND PREMEDICATION.			Prescriber	Batch			
ste	Time	Drug	Dose	Route	Sig. GMC no.	number (vaccines only)	Time given	Sig.	Pharm.
	-				-			-	-
	-			-					
									_
					-		-	-	-
	-						-		-
RUGS	ADMINIST	ERED UNDER MIDWIFER	Y EXEMPTION	AND PATI	ENT GROU	JP DIRECTI	ONS.	514	
			Dose	Route	Batch n	umber (vaccir od products	105	nt name	Sig.
ate Time		Drug							
				-	_				
					-		-		
	-								
				-	_				-
				-					
REASO	NS FOR D	RUGS NOT ADMINISTERE							11 million
Date	Time	Drug (s)	Nurses s	ignature	Reason	s(s) for non as	aministra auc	1 100 20000	Distances
	-								
									_
	_					_			1
	_								


REGULAR PRE	SCRIPTIONS	ON STREET		The second	The state of the		MONTH/Y
						() TIMES	D GHIL
	Circle target satu	ention		Target oxygen satura	tion	0800	
OXYGEN		maintain specified oxyge	n saturation	88 to 92%	94 to 98%	1200	
PRESCRIBERS SIGNATURE			DIATE			1890	
Home Oxygen Indicated: YES Referral to Respiratory Nurse	I/NO for HOOF Date:			Other:		2200	
Nurse to initial against time to	a confirm coygen is being administered an wrate is to be documented to the laft of			2L Sign]	Device	
PHARMACOLOGICAL VTE PROPHYLAXIS/TREATMENT II	ICLUDING NDACS		DOSE	ROUTE			
PRESCRIBERS	GMC No.		START	REVIEW	STOP		
INDICATION AND SPECIAL INSTRUCTIONS	19			Please tick appropria			
PHARMACY POD H PDD W				TO CONTINUE ON DISCHARGE	VES ND		
MECHANICAL VTE PROPHYLAXIS			DOSE	ROUTE			
PRESCRIBERS SIGNATURE	GMC No.		START	REVIEW	STOP		
INDICATION AND SPECIAL INSTRUCTIONS				Please tick appropria			
PHARMACY				TO CONTINUE ON DISCHARGE	I YES NO		
POO H POD W WARFARIN AND OTHER COU	MARIN ANTICOAGULANTS			Distribut	TIME	INF	
PRESCRIBERS	GMC No.				DATE	OOSE (ing)	
SIGNATURE INDICATION	DURATION	TARGET INR		PLEASE TICK APP	ROPRIATE STATUS	PRESCRIBURS	
PHARMACY	BOOK PROVIDED ON	DATE COUNSELL	ED	TO CONTINUE ON	Q YES	GIVEN BY	
POD H POD W DRUG (Approved Name)	BY.	0Y	DOSE	DISCHARGE	NO NO		
PRESCRIBERS	GMC No.		START	REVIEW	STOP		-
INDICATION AND SPECIAL INSTRUCTIONS				Please tick appropria			
PHARMACY				TO CONTINUE ON	T YES		
POD H POD W			DOSE	DISCHARGE	O NO	-	-
DRUG (Approved Name) PRESCRIBERS	GMC No.		START	REVIEW	STOP		
SIGNATURE						1.000	
INDICATION AND SPECIAL INSTRUCTIONS				Please tick appropria	CHANGE		
PHARMACY POD H POD W				TO CONTINUE ON DISCHARGE			
DRUG (Approved Name)			DOSE	ROUTI			-
PRESCRIBERS SIGNATURE	GMC No.		START	REVIEW	STOP		
INDICATION AND SPECIAL INSTRUCTIONS				Please tick appropria		-	
PHARMACY POD H POD W				TO CONTINUE ON DISCHARGE	D NO		
DMJG (Approved Name)	the first of the		DOSE	ROUTI			-
PRESCRIBERS SIGNATURE	GMC No.		START	REVIEW	STOP)
INDICATION AND SPECIAL INSTRUCTIONS				Please tick approprie			
PHARMACY				TO CONTINUE ON	LT YES		-

WHEN RE	QUIRED MEDIC	Anon										
OXYGEN				Date								Τ
CIRCLE TAR	BET OXYGEN SATU	RATION		Time	-		-	-		-		t
88-92%	94-98% O	ther		Pipel		-				-	-	ł
		Lunes		7050	-			_	-			1
DEVICE		MAX FLO	WRATE (Lines/min)	Device						-		
PRESCRIBERS SIGNATURE	GIMC No.		DAGE	Given by								Γ
DRUG Paperoved	rame)		-	Date								t
9900	ASUTE	178	ROUENCY	Time		-	-	-		-	-	+
PRESCRIBERS	GMC No.		OATE.		_	-	-	-	1	-	-	+
BIOMATURE			UNUL	Com								
INDICATION AND BPECIAL INSTRU	спонв	C NEW	PRE AO	Havin					1			Т
рналмасч		TO CONT		Chrent Dy								t
POD H POD W DRUG (Approved	rame)	DISCHAR	- L140	Owin								+
DOSE	ROUTE	1.00	SQUENCY	200								-
			10000	Time								
PRESCRIBERS SIGNATURE	GMC No.		OVGE	Cost								
INDICATION AND SPECIAL INSTRU	22/12		TIPPE AD	Route								Ť
PHARMACY	RMACY TO CONTINUE ON			Ghen	-	-	-		-	-	-	t
POD H POD W	DI N POD W DISCHARGE DI			by' Owne				_		-	-	-
Dune Nithooved	UC (Approved name)											
3900	ADUTE	799	SOUENCY	Time								
PRESCRIBERS	GIME No.		0472	GRes				1		-	-	t
INDICATION AND		-		Roda	-		-	-	-	-	-	+
BRECIAL INSTRU PHARMACY	CTIONS	1. 1. 1. 1. 1. 1. 1.	DIPRE NO					-				1
POD H PDD W		TO CONT DISCHAR		Given: by								
DRUG (Approved	лалче)			Ovile								1
DOSE	ROUTE	(Price	DOUGHCY	Time							1	t
PRESCRIBERS	GMC No.		DATE	Qdae		-	-	-	-	-	-	+
BIGNATURE INDICATION AND	it services of							-		-	_	-
SPECIAL INSTRU	стонь	1 MEW	PRE-AD	Route								
PHARMACY POD H PDD W		TO CONT DISCHAR		Given by					1			
DRUG (Approved	rand			Gain						1		1
9800	ROUTE	100	DOLENCY	79:00	-			-		-		+
PRESCRIBERI	GINC No.		DATE	- Dista	_					-		1
DIGNATURE			UNITE	Dote				_				
INDICATION AND SPECIAL INSTRU	CTIONS	I NEW	PRE AD	Route.								Γ
PHARMACY		TO CONT DISCHAR		Giren								t
POD H POD W DRUG (Approved	NATIO		1140	Date				-	-	-		-
DOSE	ROUTE	1700	QUENCY	-		-	_			-	-	-
1995				Tires								
PRESCRIBERS SIGN/TURE	GMC No.		DATE	Dote								
INDICATION AND SPECIAL INSTRU	CTIONS	Diam		Route								T
PHARMACY		TO CONT		Given	-			-	-	-	-	+
POD H POD W		DISCHAR		19								

WHEN REQU	RED MEDICA	TION	and R										I
RUG (Approved name)					Date								1
DOSE	ROUTE	FREQ	UENCY		Time	-	-	-					-
			1000				_						_
PRESCRIBER'S SIGNATURE	GMC No.		GATE		Dose								
NDICATION AND SPECIAL INSTRUCTIO	45		PRE AD		Route								
PHARMACY		TO CONTINU	IE ON C	YES NO	Given	-	-						1
POD H POO W DRUG (Approved name)		DISCHARGE] NO	Date	_	-			10000		-	-
			CONTRACT OF				_	-	-	-	-	-	4
DOSE	ROUTE	FREG	DENCY		Time								
PRESCRIBER'S SIGNATURE	GMC No.		DATE		Dase								
NOICATION AND	NC NC		TPRE AD		Route			1					1
SPECIAL INSTRUCTIO		TO CONTINU] YES	Given.		-			-			-
POD H POD W		DISCHARGE		IND	PA .			-				-	4
DRUG (Approved name					Dete								
DOSE	ROUTE	FREQ	IUENCY		Time								
PRESCRIBER'S SIGNATURE	GMC No.		DATE		Dose								Ĩ
INDICATION AND		TC: 000 075	1		Route		-	-					-
SPECIAL INSTRUCTIO	STRUCTIONS				_	-	-		-		_		
PHARMACY POD H POD W				Given	-		4						
DRUG (Approved name	¢	1.1.1.1.1.		Oate									
DOSE	ROUTE	FREC	FREQUENCY		Time								
PRESCRIBERS	GMC No.		DATE	_	Dose		-				-	-	-
SIGNATURE	ALANCE AND A				Death				-	-			-
INDICATION AND SPECIAL INSTRUCTION	INS	I NEW [PRE AD		Route								
PHARMACY POD H ROD W		TO CONTIN	UE ON D) YES	Given by								
POD H POD W DRUG (Approved neme	9				Date								Ī
DOSE	ROUTE	FRE	DUENCY		Time		-	-	-	-		-	-
BERNARD	CMC No.		DATE		Dose			-	-				_
PRESCRIBER'S SIGNATURE	GMC No.		DATE							-			
INDICATION AND SPECIAL INSTRUCTION)NS	DINEW [PRE AD		Route								
PHARMACY		TO CONTIN DISCHARG		YES	Given by								
POD H POD W DRUG (Approved name	0	DISCHORIG	- control	ON D	Date		-					-	1
OOSE	ROUTE	Types	QUENCY		Time			-	-	-	-	-	-
													_
PRESCRIBER S SIGNATURE	GMC No.		DATE		Oose							-	
INDICATION AND SPECIAL INSTRUCTION	045	NEW 1	PRE AD		Route								1
PHARMACY	2045) 	TO CONTIN	ALE ON 1	YES	Given		1						
POD H POD W	-	DISCHARD	ε	NO	Dato			-		-		-	-
DRUG (Approved nam								-		-			
DOSE	ROUTE	FRE	QUENCY		Time								
PRESCRIBER'S SIGNATURE	GMC No.	-	DATE		Dose								1
INDICATION AND		-	7.000		Route			-		-	-		1
SPECIAL INSTRUCTI	ONS		PILE AD		Given			-	-	-	-		-
PHARMACY POD H POD W		TO CONTIN DISCHARG	IE ON	YES NO	by						- 25		

Reminder: Prescribe on regular prescri	otion and state "see variable n	resc	ription			NONT E DAT	H/YEAR	0	
Reminder: Prescribe on regular prescrip	pron and state see variable p				96 = 1 TIMES	0,em	59	Urits	
DRUG (Approved name)			ROUTE	S/C					-
	51/			STOP	Breakfast			1	1
RESCRIBERS GMC No. SIGNATURE	310			3101	Lunch				1
DEVICE	Please tick appropria		us.		Dinner		1		
	C NEW C PRE				Night		1		-
PHARMACY	TO CONTINUE ON D	CHAB	IGE IN	E5 10			1		1
POD H POD W		-	ROUTE			-	+		t
DRUG (Approved name)			SUGIE.	S/C	-	-	-	-	-
man to	57.	ART	-	STOP.	Breakfast				1
PRESCRIBERS GMC No. SIGNATURE					Lunch		1	-	1
DEVICE	Please tick appropria		tue		Dinner				1
	D NEW D PRE	100			Night				1
FHARMACY	TO CONTINUE ON D	SCHAI	RGE O	10		-	-	-	Ť
POD H POD W						-	-	+	ñ
DBUG (Approved name)			NOUTE	S/C		-	-	-	ł
SERVICES GMC No.	51	ART		STOP	Breakfast		1		-
PRESCHIBERS GMC No. SIGNATURE					Lunch		1	-	1
DEVICE	Please tick appropri		itut		Dinner				-
	I NEW I PRE				Night				100
PHARMACY	TO CONTINUE ON D	ISCHA	RGE []	NO NO		-	1	1	Ţ
POD H POD W						1	1	-	1

min bevorge) 20m	n).			Oute			_	
DOSE (UNITS)	ROUTE S/C	FREQU	JENICY	Time				
PRESCRIBERS SIGNATURE	GMC No.		DATE	DOSE (In Units)				
NDICATION AND RECIAL INSTRUCTION	5			Route				
PHARMACY				Given by				
DRUG (Approved nam	a)			Dete				
DOSE (UNITS)	ROUTE S/C	Time						
PRESCRIBERS	GMC No.	-	DATE	005E (in Units)				
INDICATION AND SPECIAL INSTRUCTION	15			Route				
PHARMACY				diven by	-			
DRUG (Approved nam	18)			Date				
DOSE (UNITS)	ROUTE S/C	FRED	NENCY	Time				
PRESCHIBERS SIGNATURE	GMC No.		DATE	(DOSE (in Units)				
INDICATION AND SPECIAL INSTRUCTION	5			Route			-	-
PHARMACY				Given by				



		CRIPTIO	NS ONLY			LEATE	_	-	-	-	
DRUG (Approve	ed name)		DOSE		ROUTE						
PRESCRIBER'S	GMC No		INDICATION (M	ANDATO	DRY)						
SIGNATURE			3RD REVIEW	STOP	93853				1		1 1
START	48 HOUR REVIEW	2ND REVIEW DATE / TIME	DATE / TIME	arue				-			
REVIEWED										-	
BY = PHARMACY							-	-	-	-	
POD H POD W	1				and the second se	DVX =		-		-	-
DRUG (Approv	ed name)		DOSE		ROUTE	S. Testes	-	-	-	-	
Persent Charles								-	-	-	
PRESCRIBER'S	GMC N	a.	INDICATION (N	ANDAT	ORY)		-	-	-	-	
SIGNATURE	48 HOUR REVIEW	2ND REVIEW DATE / TIME	3RD REVIEW DATE / TIME	STOP				-	+	-	-
REVIEWED											
BY == PHARMACY											
POD H POD W	V		-			DATE ==			-	-	-
DRUG (Approv	ved name)		DOSE		ROUTE	1 10/05			1		
0.00									-		
PRESCRIBER'S	GMC N	0.	INDICATION (I	ANDAT	ORY)			-	-	-	-
SIGNATURE START	48 HOUR REVIEW	2ND REVIEW DATE / TIME			P			-	-		
								_	-		
REVIEWED											
REVIEWED BY = PHARMACY							_	-	-		
BY =	N					PMI O					
BY = PHARMACY			DOSE		ROUTE	BATK O CTEMES					
BY = PHARMACY POD H POD V			10,8119		1.000	BANK U STRAFF					
BY = PHARMACY POD H POD V DRUG (Approv	ved name)	lō.	DOSE INDICATION (MANDA	1.000	DATE O E TIMER					
BY = PHARMACY POD H POD V DRUG (Approv	ved name)		INDICATION (510	TORY)	BATE O					
BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED	ved name) GMC N	2ND REVIEW	INDICATION (510	TORY)	BACK C					
BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START	ved name) GMC N	2ND REVIEW	INDICATION (510	TORY)	BATS O					
BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED BY =	GMC N GMC N 48 HOUR REVIEW	2ND REVIEW	INDICATION (510	TORY)						
BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED BY = PHARMACY	GMC N GMC N 48 HOUR REVIEW	2ND REVIEW	INDICATION (510	TORY)	BATE-O C There I DATE-O I DATE-O I TIMES					
BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED BY = PELARMACY POD H POD V	GMC N GMC N 48 HOUR REVIEW W W	2ND REVIEW DATE / TIME	INDICATION (BATE / TIME DOSE	510	ROUTE						
BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED BY = PHARMACY POD H POD V DRUG (Appro PRESCRIBER'S	GMC N GMC N 48 HOUR REVIEW W W	2ND REVIEW DATE / TIME		MANDA	ROUTE TORY)						
BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED BY = PHARMACY POD H POD V DRUG (Appro	GMC N GMC N 48 HOUR REVIEW W W	200 REVIEW DATE / TIME No.	INDICATION (DATE / TIME DATE / TIME DOSE INDICATION I	MANDA	ROUTE TORY)						
BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED BY =	W GMC N Ha HOUR REVIEW W W Wed name) GMC N	No.	INDICATION (DATE / TIME DATE / TIME DOSE INDICATION I	MANDA	ROUTE TORY)						
BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED BY = PHARMACY	Ved name) GMC N AB HOUR REVIEW W W Wed name) GMC R AB HOUR REVIEW	No.	INDICATION (DATE / TIME DATE / TIME DOSE INDICATION I	MANDA	ROUTE TORY)						
BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED BY =	Ved name) GMC N AB HOUR REVIEW W W Wed name) GMC R AB HOUR REVIEW	No.	INDICATION (DATE / TIME DATE / TIME DOSE INDICATION I W BRD REVIEW DATE / TIME	MANDA	ROUTE TORY)	BATES ETENSES					
BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED BY = PHARMACY	Ved name) GMC N AB HOUR REVIEW W Ved name) GMC R AB HOUR REVIEW W W	No.	INDICATION (V 3RD REVIEW DATE / TIME DOSE INDICATION (W SIND REVIEW DATE / TIME DATE / TIME DATE / TIME	MANDA V STO	ROUTE TORY) TORY) P	BATES ETENSES					
BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGNATURE START REVIEWED BY = PHARMACY POD H POD V DRUG (Appro PRESCRIBER'S SIGNATURE START REVIEWED BY = PHARMACY POD H POD V DRUG (Appro PRESCRIBER'S	Ved name) GMC N 48 HOUR REVIEW W W GMC R GMC R GMC R 48 HOUR REVIEW W W Solution	No.	INDICATION (DATE / TIME DATE / TIME DOSE INDICATION I W BRD REVIEW DATE / TIME	MANDA V STO	ROUTE TORY) TORY) P	BATES ETENSES					
BY = PHARMACY POD H POD V DRUG (Approv PRESCRIBER'S SIGMATURE START REVIEWED BY = PHARMACY POD H POD V DRUG (Appro PRESCRIBER'S SIGNATURE START REVIEWED BY = PHARMACY POD H POD V DRUG (Appro	Ved name) GMC N 48 HOUR REVIEW W W GMC R GMC R GMC R 48 HOUR REVIEW W W Solution	No.	INDICATION (V 3RD REVIEW DATE / TIME DOSE INDICATION I DATE / TIME DOSE INDICATION U DATE / TIME DATE	MANDA V STO	ROUTE ROUTE TORY) P ROUTE ROUTE	BATES ETENSES					

	MRSA Status	New	Y	Previous Admission			C. Dif Status	S 1.19	ew	Previous Admission
,	Use ge	ntami must l	cin ca be tak	ENTAMIC leulator of en 6 to 14 ne 5mg/kg	r intrans hours af	et to calcu	ilate dos rst dose	e. has bee	en give	n.
	Indication Date to be given	Time to be given	Dose (mg)	Prescribers stgnature GMC No.	Date of sig.	Start time of infusion	Given by: (sign)	Dute an blood le taken		Gentamicin Levels mg/l
,										
	have b INDIC CURB CLRE Check microl consul Doses clearar	timicrobi een agree CATION, 165 score previous biology re tant micr need to b ace use ca	al preser ed by Mi , STOP , STOP relevan esults da obiologi e adjust alculator	iptions MUST icrobiology. See AND REVIEW be recorded for t microbiology ily. If a patient st. ed to suit patient on intranet and be reviewed at 4	e full up to o V DATES N r all commu results befor is not respon it's age, size I see dose au	late policy on IUST BE RE nity acquired re prescribing nding to treatr and renal fun djustments for	intranet. CORDED (pneumonia, antibiotics a nent seek ad ction. To cal antibiotics.	ON THE and check lvice from lculate cre	CHART. new	
	IV SWIT Patient ab Temperat	VES to a VES to a ble to swa ure settlin e <100bpr	UIDEI III, cons Illow and ng and < m for las	JINES ider change to i tolerate oral fl 38°C for at leas t 12hrs?	ORAL uids?	Oral rout Continuir		to any, r sed? psis?	emain on	IV
	(no unexp WCC bet Oral form Others m BP stable Respirato	ween 4-1 iulation a arkers: ry rate <2	2x10%L/ vailable/	? ? is/min		(Mening) neutroper immunoc severe in		ditis, ence brosis, sep d pts, cont liscussed v	phalitis, o sticaemia, inuing sep with micro	steomylitis, haematology osis, other
	CRP retur	ning to n	ormal as	nd less than 100	(adult)					

				Did patient experience adverse reaction? [Yes/No] ◀	Vas / No	Yes / No	Yes / No	Ves / No	Vers / No	Vas / No	Yes / No	Yes / No	Yes / No	Yes / No	EDICAL	
		1	l	Given by/ by											ENT'S MI	0
			DBULINS)	Start time / stop time											d bank)/ IN THE PATI	
Name:	Hospital Number: NHS Number:	Date of Birth:	(INCLUDING INTRAVENOUS IMMUNOGLOBULINS)	(Attach sticker)											Complete label attached to blood product. Detach and return bottom portion via the pink wallet (if available, if not please post to Blood bank)/ «IF THE PATIENT EXPERIENCES TRANSFUSION RELATED PROBLEMS THESE MUST BE CONTEMPORANEOUSLY RECORDED IN THE PATIENT'S MEDICAL NOTES, AND A TRANSFUSION REACTION FORM AND INCIDENT FORM COMPLETED.	0
	4o?		ICLUDING	Signature GMC No.											ik wallet (if a UST BE COI RM AND INC	
	s / No?		1	Duration / rate of infusion											n via the pir IS THESE M ACTION FO	
D PRODUCTS	idicate as appropri is appropriate) Ye		Statement of	Drugs required to cover infusion (must be presided on once only section of chard)											um bottom portio LATED PROBLEM RANSFUSION RE	4
O BLOO	Iood? (Is (Indicate a		ED	Route							_				h and ret JSION RE	
DDED T(gative b blood?		INISTER	Total volume											uct. Detach and TRANSFUSION NOTES, AND	
NOTE: DRUGS MUST NOT BE ADDED TO BLOOD PRODUCTS	Does the patient require CMV negative blood? (indicate as appropriate) Yes / No? Does the patient need irradiated blood? (indicate as appropriate) Yes / No?		BLOOD PRODUCTS TO BE ADMINISTERED	Blood product											oel attached to blood prod	
VOTE: DRI	Does the p Does the p		BLOOD PR	Date and Time to be administered											complete lat ◄IF THE	

Pharm.								
	checked by	 	 	 	 	 	 	
Start	time							
Signature	GMC No.							
	non							
Complete either or	Rate							
Rotte		ı.						
	volume							
DUS / SUBCUTANEOUS INFUSION	number on the second							
DRUGS TO BE ADMINISTERED BY INTRAVENOUS / SU	Intusion solution							
TO BE ADI	Time							
RUGS	Date							



TCA Overdose Guidance

OVERVIEW

<u>Commonly encountered drugs</u>: **amitriptyline**, imipramine, **clomipramine**, desipramine, **dosulepin** (dothiepin), lofepramine, nortriptyline

Although not the first line choice for depression having lost place to SSRIs, TCAs have proven efficacy and are also used for behavioural disorders, eating disorders, neuropathic pain and migraine

TCA overdose is **one of the commonest causes of death from poisoning**. UK figures from Office of National Statistics (2011): 200 deaths out of 2652 recorded overdoses

Half of the in-hospital fatalities will have trivial toxicity on arrival to hospital but develop major toxicity within 1 hour; this is due to rapid absorption from the GI tract and saturation of hepatic enzymes responsible for metabolism

PHARMACOLOGY

As always, toxic effects of TCAs are predictable from knowledge of their basic pharmacology!

Therapeutically, TCAs **primarily block serotonin and noradrenaline reuptake**, increasing their available concentrations (?mechanism of action in depression)

They are pharmacologically "dirty" and **also block histamine and cholinergic muscarinic** receptors and sodium and other membrane ion channels

<u>KINETICS</u>

They are rapidly absorbed and undergo enterohepatic recirculation

They are largely (>90%) bound in the plasma to alpha-1-acid glycoprotein but **acidosis increases** free drug concentration, augmenting toxicity...

...this explains the use of **alkalinisation** to treat toxicity. Free concentrations of drug fall by 20% when pH rises from 7.0 >> 7.4 and by 42% over a pH range of 7.4 - 7.8

MECHANISM OF ACTION

RECEPTOR	ACTION	EFFECT	ΤΟΧΙΟΙΤΥ
Na+ channels	Blockade	Prolong phase 0 of cardiac action potential	Widened QRS Dysrhythmias

RECEPTOR	ACTION	EFFECT		ΤΟΧΙΟΙΤΥ
K+ channels	Blockade	Prolong phase 3 of cardiac action potential	Pro	longed QT
	nitochondrial osphorylation	Direct depression of cardiac myocytes	Нур	ootension (late)
alpha-1 adrenergic	Blockade	Vasodilatation	*	
NA & 5HT reuptake	Blockade	Hypertension and tac	hyca	ardia (early) *
Muscarinic	Blockade	Classic anticholinergic effects: dry mouth, blurred vision tachycardia, ileus urinary retention	n	Tachycardia Delirium
Histamine	Blockade	Sedation		Drowsiness

Seizures are well-known but they are **idiosyncratic**; the mechanism is poorly understood (Na+ channel blockade should theoretically be protective). Possible GABA effect?

CLINICAL FEATURES

In acute TCA overdose there are three major toxic syndromes

• ANTICHOLINERGIC SYNDROME

- Dry mouth
- Blurred vision (moderate pupillary dilatation/cycloplegia)
- Tachycardia
- Ileus
- Urinary retention

In addition, patients may show central signs of **delirium**; this is not a discrete entity but a spectrum of symptoms and signs. Delirium may persist for several days

- Hypervigilance
- Suspicion
- Disorientation
- Hallucinations

CARDIAC TOXICITY

The cardiovascular response is **biphasic**

Initial state is one of **tachycardia and hypertension** due to blockade of noradrenaline reuptake and the anticholinergic effects With sovere toxicity this decays to **bypetension** and (relative) bradycardia due to

With severe toxicity this decays to **hypotension and (relative) bradycardia** due to the blockade of alpha-1 receptors and direct myocardial depression This may be compounded by severe, refractory **dysrhythmia** ECG changes are multitude; see investigations section. Of particular concern are **widened QRS** and **bradycardia** which may signal **imminent cardiac arrest**

Sinus tachycardia AF and atrial flutter SVT VT VF Bradycardia >> asystole

CNS TOXICITY

- •Sedation > coma
- •Delirium (see Anticholinergic Syndrome)
- •Hyperreflexia including myoclonus
- Seizures

Seizures can be very difficult to treat - get help!

KEY INVESTIGATIONS

ECG

Perform an ECG early! The ECG is the most accurate predictor of toxicity for the majority of tricyclic antidepressant poisonings

Minor ECG changes are common:

- •Sinus tachycardia
- •Increase in the PR interval
- •Nonspecific T-wave changes

More serious changes reflect altered conduction through Purkinje fibres due predominately to sodium channel blockade. Measurements that predict major toxicity include:

- Prolonged QRS (>100ms)
- Right axis deviation or RBBB
- •Height of R wave and R/S ratio in aVR > 0.7
- •Brugada syndrome

Arterial Blood Gases (ABG)

In severe poisonings a mixed respiratory and metabolic acidosis is common

Assess adequacy of ventilation in patients with decreased GCS - a respiratory acidosis (increased PCO2) mandates ventilatory support

Assists in monitoring treatment with **systemic alkalinisation**. Hypoxia may be due to a number of the pulmonary complications seen in TCA poisoning including aspiration, cardiac and non-cardiac pulmonary oedema.

Venous Blood

Perform as part of routine workup; need to exclude multidrug OD so paracetamol & salicylate levels are mandatory

Hypoglycaemia is not a feature, but must be ruled out in any patient with a reduced level of consciousness

TCA levels cannot be assayed in a clinically useful time

TREATMENT - SUPPORTIVE

A Is the airway patent? Deteriorating levels of consciousness will likely mandate ventilatory support

Perform basic airway manoeuvres (head tilt/chin lift/jaw thrust) and get help!

Use airway adjunct if necessary

- •Oropharyngeal airways (Guedel airway) can be attempted but are generally not tolerated unless patient is very obtunded
- •Nasopharyngeal airways are often better tolerated in semi-conscious patients but even expert insertion may cause epistaxis and worsen airway

B Assess for adequacy of ventilation, rule out pulmonary aspiration and perform **arterial blood gas (ABG)**

C All patients should have **continuous ECG monitoring** for at least 6 hours after ingestion

Correct hypotension with intravenous fluid

After cardiac arrest, prolonged resuscitation may be successful and should be continued for at least 1 hour

GI Decontamination

Due to rapid absorption, only relevant if presentation within 1 - 2 hours of ingestion. Use activated charcoal

Most patients with massive ingestions will be unconscious or have a deteriorating level of consciousness by 2 hours and should be intubated. If the patient is unconscious and requires intubation to protect the airway insert an orogastric tube, aspirate stomach contents then give activated charcoal.

TREATMENT - SPECIFIC

** Alkalinisation with sodium bicarbonate **

After supportive measures, this is the **key intervention.....but by this point ITU should be involved**!

Triple benefit - **reduction in free drug concentration**, correction of acidosis with beneficial haemodynamic effects, and probably Na+ loading with membrane-stabilising effect

Alkalinisation will result in increased CO2 production, so adequate ventilation is required

Sodium bicarbonate (NaHCO3)

Use 8.4% solution (MiniJet on cardiac arrest trolley) Dose given in most sources is (annoyingly) in mEq (milliequivalents)/kg But happily, 1 ml of 8.4% solution = 1mEq of NaHCO3, so **DOSE (initial):** 1 mEq/kg or **1ml/kg of 8.4% solution** Can repeat bolus if required (total: 1 - 3 ml/kg) Aim for a pH of 7.50 - 7.55 The initial treatment in critically ill patients is often titrated against clinical response with bolus injections of 1-3 mEq of sodium bicarbonate per kg body weight repeated at 3-5 minute intervals. When the clinical situation allows it, arterial blood pH should be checked. The target pH is 7.50 - 7.55, sustained elevations of pH greater than this are associated with impaired oxygen dissociation from hemoglobin. As the patient is usually ventilated the pH can be maintained with mild hyperventilation (pCO2 = 30 mmHg).

Seizures

- •Treated with diazepam (0.15 mg/kg, repeated) or lorazepam (4mg) IV initially
- •** Avoid phenytoin ** it is a Na+ channel blocker and may aggravate TCA overdose
- •Follow with phenobarbitone 15-18 mg/kg IV
- •Refractory seizures >> GA

Seizures will worsen acidosis thereby increasing free TCA concentrations, so prompt treatment is essential

Anticholinergic delirium

- •Mild: reassurance +/- benzodiazepines
- •Severe: generally requires large doses of **benzodiazepines**; neuroleptics should be avoided

Arrhythmias

- •Can be difficult to differentiate
- •Correction of hypoxia administer O2
- •Correction of acidosis (see later)

Antiarrhythmic agents should be avoided unless arrhythmias are unresponsive to the aforementioned measures - **get expert advice**